Surgeons and anesthesiologists have successfully coalesced around a unified, day-of-surgery multimodal analgesic algorithm for primary total knee arthroplasty (TKA). This highly structured, modern framework standardizes patient comfort: patients receive a pre-emptive cocktail of oral acetaminophen, a nonsteroidal anti-inflammatory drug (NSAID), and a systemic glucocorticoid. Spinal anesthesia provides stable preemptive baseline blockades while facilitating hypotensive orchestration for localized blood conservation. This is rounded out by a regional local anesthetic, deployed seamlessly as a selective peripheral nerve block and/or a deep periarticular injection. Postoperatively, patients are quickly ambulated, provided with tightly titrated oral opioids on an as-needed baseline, and safely discharged home with a structured icing and oral medication regimen.
Yet, despite the overwhelming clinical success of this non-premium pathway, corporate-backed clinical trials continue to push liposomal bupivacaine (Exparel). This modality continues to enjoy a wave of disproportionate enthusiasm among select administrative boards that is completely divorced from its real-world clinical efficacy. A recent high-profile, multicenter randomized controlled trial by Gadsden et al. studied the addition of liposomal bupivacaine against a dilutional saline control within a standard bupivacaine adductor canal block across 167 knee patients, reporting a 25% drop in 96-hour post-operative opioid usage. However, a closer look at the basic science chemistry behind the trial layout reveals a fatal structural flaw that completely compromises the validity of these commercial claims.
